Skip to content

XOMA Corporation XOMA Operating lease liabilities

Operating lease liabilities at other companies

Theravance Biopharma logo
Theravance BiopharmaTBPH
Roivant Sciences logo
Roivant SciencesROIV
BridgeBio Pharma logo
BridgeBio PharmaBBIO
XER
Xeris Biopharma Holdings, Inc.XERS

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's operating lease liabilities?
XOMA Corporation (XOMA) reported operating lease liabilities of -$656K in Q1 2026.
How has XOMA Corporation's operating lease liabilities changed year-over-year?
XOMA Corporation's operating lease liabilities decreased by 507.4% year-over-year, from -$108K to -$656K.
What is the long-term trend for XOMA Corporation's operating lease liabilities?
Over 4 years (2021 to 2025), XOMA Corporation's operating lease liabilities has grown at a 48.7% compound annual growth rate (CAGR), from -$179K to -$876K.